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Pathogenesis and management of hepatorenal syndrome
in patients with cirrhosisq
Paolo Angeli, Carlo Merkel*,
Department of Clinical and Experimental Medicine, University of Padova, via Giustiniani 2, 35126 Padova, ItalyHepatorenal syndrome is a severe complication of advanced liver cirrhosis, in patients with ascites and marked circu-
latory dysfunction. It is clearly established that it has a functional nature, and that it is related to intense renal vasocon-
striction. Despite its functional origin, the prognosis is very poor. In the present review, the most recent advances in
diagnosis, pathophysiology, and treatment are discussed. Recent developments in pathophysiology are the basis of the
new therapeutic strategies, which are currently under evaluation in randomised clinical trials.
 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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The occurrence of liver failure in patients with cirrho-
sis was ﬁrst described during the 19th century, but the
term hepatorenal syndrome (HRS) was ﬁrst introduced
in 1932 by Helvig and Schutz [1] to describe a condition
of acute renal failure occurring after biliary tract surgery
in patients who showed a pathological pattern of acute
tubular necrosis or tubular interstitial nephritis. Later
on, this term reached a very wide diﬀusion, and was gen-
erally used to describe any kind of simultaneous severe
impairment of liver and renal function. When, in the
middle of the century it became progressively under-
stood that pathophysiology of acute renal failure is0168-8278/$34.00  2008 European Association for the Study of the Liver.
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of disease, it was clearly shown that renal involvement
in advanced liver disease was generally a functional
form of renal failure [2].
Further studies showed that functional renal failure
in advanced cirrhosis may be further divided into two
forms, a more frequent, easily reversible and less severe
condition of pre-renal failure due to vascular underﬁll-
ing (bleeding, diarrhoea, excessive use of diuretics, heart
failure), and a more severe condition, which is character-
ized by intense renal vasoconstriction and is similar in
pathophysiological characteristics to conventional pre-
renal failure, but does not improve after correction of
vascular underﬁlling. The term HRS was thus restricted
to this form of unexplained pre-renal failure in the
course of advanced liver disease [3]. Around the same
time, it was observed that kidneys of patients dying of
HRS could be successfully transplanted to patients with
organic renal failure [4], and it was shown that the
intense renal vasoconstriction, which is usually observed
at renal arteriography in patients with HRS (Fig. 1), dis-
appeared at post-mortem vascular injection [5], empha-
sizing the functional nature of such renal insuﬃciency.
In the last few years, there has been an extensive
debate on the optimal criteria to deﬁne HRS and the
ﬁrst consensus deﬁnition was agreed upon at the 1994
meeting of the International Ascites Club [6] (Table 1).Published by Elsevier B.V. All rights reserved.
Fig. 1. Intense renal vasoconstriction with poor ﬁlling of arterial cortical
vasculature at selective right renal arteriography in a patient with
hepatorenal syndrome (Personal observation, 1975).
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ria, it soon became apparent that there were some ambi-
guities and pitfalls in the deﬁnition of HRS, and that
new and more precise diagnostic criteria were required.
These new criteria were developed by the International
Ascites Club at a focused study group held in San Fran-
cisco in 2006, and reported in 2007 [7] (Table 2). It is evi-
dent that this new deﬁnition is more precise (clear
deﬁnition of the procedures requested to exclude a pre-
renal failure), but is less strict than the previous one,
since patients with recent or present infections, in partic-
ularly spontaneous bacterial peritonitis (SBP), are not
excluded from a diagnosis of HRS.Table 1
International Ascites Club’s diagnostic criteria of hepatorenal syndrome (1996
Major criteria:
- Chronic or acute liver disease with advanced hepatic failure and portal h
- Low glomerular ﬁltration rate (s-creatinine >1.5 mg/dL or creatinine clea
- Absence of shock, ongoing bacterial infection, and current or recent trea
(repeated vomiting or intense diarrhoea) or renal ﬂuid losses (weight l
1000 g/day in patients with peripheral edema)
- No sustained improvement in renal function (decrease in s-creatinine to
more) following diuretic withdrawal and expansion of plasma volume wi
- Proteinuria <500 mg/day nad no ultrasonographic evidence of obstructiv
Additional criteria (not necessary for the diagnosis):
- Urine volume <500 mL/day
- Urine sodium <10 mEq/L
- Urine osmolality greater than plasma osmolality
- Urine red blood cells <50/HPF
- Serum sodium concentration <130 mEq/LSuch changes should be taken into consideration
when comparing treatment results of new studies with
those obtained in the previous years, because changes
in deﬁnitions may lead to a sort of stage migration, a
phenomenon that is well known to bio-statisticians [8],
and is characterized by an improvement in outcome in
both stages involved (Fig. 2). Indeed, if patients with
infections unresponsive to a 2-day infusion of albumin
have a mortality rate intermediate between classical
HRS and pre-renal azotemia (with the values suggested
in the ﬁgure), the migration of these patients towards the
group of patients with HRS would decrease mortality in
HRS from 80% to 65%, and that of pre-renal azotemia
from 27.5% to 20%.2. Natural history
HRS is a potentially reversible form of renal failure
that occurs in patients with cirrhosis and ascites as well
as in patients with acute liver failure. In cirrhotic
patients with ascites, pre-renal failure (42%) and acute
tubular necrosis (ATN) (38%) represent the most com-
mon forms of acute renal failure while HRS [9] is some-
what less frequent (20%) (Table 3). The incidence of
HRS in patients with cirrhosis and ascites is equal to
18% after 1 year, and reaches 39% after 5 years [10].
In almost half the cases of HRS, one or more precipitat-
ing factors may be identiﬁed, including bacterial infec-
tions (57%), gastrointestinal hemorrhage (36%), and
large volume paracentesis (7%) [10].
HRS is characterized by (a) marked renal vasocon-
striction with a consequent reduction in renal plasma
ﬂow and glomerular ﬁltration rate, (b) the absence of
pathological changes in the renal tissue, and (c) pre-
served renal tubular function. HRS usually arises when
the chronic liver disease is associated with a marked cir-
culatory dysfunction with low values of arterial pressure
despite an overactivity of the sympathetic nervous and
renin–angiotensin systems, which, according to the; Ref. [6])
ypertension
rance <40 mL/min)
tment with nephrotoxic drugs. Absence of gastrointestinal ﬂuid losses
oss >500 g/day in patients with ascites without peripheral edema or
1.5 mg/dL or less, or increase in creatinine clearance to 40/mL/min or
th 1.5 L of isotonic saline
e uropathy or parenchymal renal disease
Table 2
New International Ascites Club’s diagnostic criteria of hepatorenal syndrome (2007; Ref. [7])
- Cirrhosis with ascites
- Serum creatinine > 1.5 mg/dL
- No improvement in serum creatinine (decrease to a level of <1.5 mg/dL) after at least 2 days with diuretic withdrawal and volume expansion
with albumin. The recommended dose of albumin is 1 g/kg of body weight per day up to a maximum of 100 g/day
- Absence of shock
- No current or recent treatment with nephrotoxic drugs
- Absence of parenchymal kidney disease as indicated by proteinuria >500 mg/day, microhematuria (<50 RBC/high power ﬁeld) and/or
abnormal renal ultrasonography
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quence of a marked arterial vasodilation, mainly located
in the splanchnic circulation [11]. Until a few years ago,
the prognosis of cirrhotic patients developing HRS was
very poor with mortality reaching 100% in some series,
and a median survival time of two weeks from diagnosis
[10]. Thereafter, some new promising treatments of HRS
have been proposed, and improvement in survival has
been observed in some studies.Table 3
Acute renal failure in patients with cirrhosis and ascites (Ref. [9])
1. Acute tubular necrosis (41.7%)
2. Pre-renal failure (38%)
3. Hepatorenal syndrome (20%)
4. Post-renal failure (0.3%)3. Diagnosis of HRS
The diagnostic criteria for a diagnosis of HRS have
been reported above in the introduction (Tables 1 and
2). Within the diagnostic category of HRS, two diﬀerent
types of HRS can be distinguished (Table 4). Type-1
HRS is characterized by a rapid progression of renal
failure; therefore the main clinical presentation is overt
acute renal failure. By contrast, in patients with Type
2 HRS the degree of the impairment of renal failure is
less severe and more stable over time. As a consequence,
the main clinical problem in these patients is refractory0%
100%
Old definition
Pre-renal failure Infections unresp
Mortality 80%
Mortality 50%
Mortality 20%
}
} =80%
=27.5%
Fig. 2. Expected changes in mortality rate of HRS and of pre-renal failure acc
HRS because of the stage-migration eﬀect of patients with infections not respo
approximate and only used for exemplifying purpose.ascites (Table 4). The two types of HRS substantially
diﬀer in prognosis, since median survival of type-1
HRS averages 2 weeks, whilst that of type 2 is generally
around 4–6 months [12]. Besides the obvious diﬀerences
in the severity of renal function impairment, further
pathophysiological diﬀerences between type-1 and
type-2 HRS are not fully elucidated, and it is not clearly
deﬁned if the two types share all the same pathophysio-
logical mechanisms; nevertheless, it may be observed
that Type-1 HRS is often induced by a precipitating
event (Table 5), in particular spontaneous bacterial peri-
tonitis [13,14]. Almost one third of patients with sponta-
neous bacterial peritonitis develop a progressive form of
renal failure [13,14] which in most cases fulﬁls the most
recent diagnostic criteria of type 1 HRS [14]. MoreNew definition
ondent to 2-d alb Classical HRS
Mortality 80%
Mortality 50%
Mortality 20% }
} =65%
=20%
ording to the old (1996 – Ref. [6]) and new (2007- Ref. [7]) deﬁnitions of
nding to a 2-day course of albumin. Frequencies and mortality rates are
Table 4
Clinical types of hepatorenal syndrome (Ref. [7])
- Type-1 hepatorenal syndrome: rapidly progressive reduction of renal function as deﬁned by doubling of the initial s-creatinine to a level
>2.5 mg/dL (226 lM/L) in less than two weeks
Clinical pattern: acute renal failure
- Type-2 hepatorenal syndrome: moderate renal failure (s-creatinine ranging from 1.25 to 2.5 mg/dL or 113–226 lM/L) with a steady or slowly
progressive course
Clinical pattern: refractory ascites
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precipitated in cirrhotic patients with ascites by all types
of bacterial infections. In most cases renal failure is tran-
sient and recovers after the resolution of the infection.
However, in some cases an acute renal failure with the
hallmarks of type 1 HRS can also be precipitated by uri-
nary, biliary, or intestinal infections [15]. The risk fac-
tors for the development of renal failure after bacterial
infections are (a) the severity of infection, (b) the MELD
score at the diagnosis of infection and (c) the persistence
of infection despite antibiotic treatment [15,16]. In addi-
tion, the risk of developing type-1 HRS following a bac-
terial infection is higher in patients with cirrhosis who
already present a type-2 HRS [13,14]. There are some
observations suggesting that type-1 HRS in this clinical
situation may occur as a consequence of an abrupt and
severe additional deterioration in circulatory dysfunction
characterized by a further enhancement in splanchnic
arterial vasodilation and a decrease in cardiac output.4. Pathophysiology of HRS
The causes of the intense renal vasoconstriction
underlying the occurrence of HRS are not fully under-
stood. Compared to control subjects or cirrhotic
patients with ascites but without HRS, patients with
HRS consistently show lower splanchnic vascular resis-
tance. Renal vasoconstriction, which is the pathophysi-
ological basis of HRS, therefore develops in a context
of a marked reduction of eﬀective circulating volume
related to peripheral arterial vasodilation [6,13]. The
involvement of endogenous vasoconstrictor systems
induced by the reduction of eﬀective circulating volume
in the development of HRS is clearly shown in clinical
[17–19] and experimental studies [20]. The most recent
advances in our understanding of the pathogenesis of
HRS have focused on mainly two new aspects. The ﬁrst
one is that the peripheral arterial vasodilation occurs
mainly in the splanchnic arterial vascular bed and theTable 5
Precipitating events of hepatorenal syndrome
- Spontaneous bacterial peritonitis
- Paracentesis without plasma expansion
- Gastrointestinal hemorrhage
- Alcoholic hepatitissecond is that in patients with cirrhosis and HRS, the
modulation of cardiac output is relatively unable to pre-
vent the severe reduction of eﬀective circulating volume
due to the splanchnic arterial vasodilation.
The ﬁrst of these concepts has been formulated on the
basis of the results of some clinical studies in which
Doppler ultrasonography was used to evaluate regional
blood ﬂow in cirrhotic patients. These studies consis-
tently demonstrated that arterial vasodilation occurs in
the splanchnic circulation in patients with cirrhosis,
while arterial vasoconstriction occurs in other vascular
beds, including renal, brachial, femoral, and cerebral
beds [21–28]. At the same time, clinical studies directed
to assess tissue-related blood ﬂows, such as cutaneous
and muscular blood ﬂows, gave contrasting results,
ranging from low to normal or even increased values
[29]. These discrepancies were also dependent on the
methods used to estimate blood ﬂow, which included
color Doppler ultrasonography [21,30], nuclear medi-
cine techniques [31], and plethysmography [32]. The
main clinical problem related to abnormalities of muscle
blood ﬂow is the occurrence of muscle cramps, which
may be improved by a chronic expansion of eﬀective
plasma volume by means of albumin administration
[33], a procedure which probably contributes to correct
the abnormalities of muscle blood ﬂow.
Splanchnic arterial vasodilatation is thought to be the
consequence of an increased release of endogenous vaso-
dilators due to portal hypertension and/or hepatic fail-
ure. Among the endogenous vasodilators, nitric oxide
[34], carbon monoxide [35], glucagon [36], prostacyclin
[37], adrenomedullin [38] and endogenous opiates [39]
seem to be the most clearly involved. A detailed analysis
of all possible vasodilators involved in the pathogenesis
of splanchnic arterial vasodilations goes beyond the pur-
poses of this paper; however it is apparent that several
endogenous vasodilators can contribute to splanchnic
arterial vasodilation in every stage of progression of cir-
rhosis, and that the relative role of each of them can
vary in the diﬀerent stages of the liver disease [40].
Indeed, early in the course of the disease, the decrease
in the systemic vascular resistance due to the arterial
splanchnic vasodilation is compensated by the increase
in heart rate and in cardiac output (the so-called ‘‘hyper-
dynamic circulation”). However, as the liver disease pro-
gresses leading to a further impairment in portal
hypertension and hepatic failure, the hyperdynamic cir-
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ity of the reduction of the eﬀective blood volume due to
the splanchnic arterial vasodilation. This leads to a fur-
ther activation of the systemic endogenous vasoconstric-
tor systems (the sympathetic nervous system, the renin–
angiotensin system, and the non-osmotic release of
vasopressin). The activation of these systems is thought
to be the main eﬀerent mechanism of the functional
renal abnormalities which characterizes the course of
the liver disease such as, renal sodium retention leading
to ascites, renal water retention leading to hyponatre-
mia, and severe arterial renal vasoconstriction leading
to HRS. HRS develops during the most advanced stages
of cirrhosis in the presence of an extreme reduction of
the eﬀective blood volume and, as a consequence, in
presence of a extreme activation of the systemic vaso-
constrictor systems [22].
A study from our laboratory seems to conﬁrm that
HRS is the clinical equivalent of the extreme reduction
of the eﬀective blood volume due to splanchnic arterial
vasodilation with an extreme hyperdynamic circulation
since we observed higher heart rate and higher cardiac
output in patients with cirrhosis and type-2 HRS than
in those without HRS [41]. However, these observations
were not in agreement with some previous studies which
reported that in HRS cardiac output was similar or even
reduced as compared to normal subjects or to patients
with cirrhosis without HRS or without refractory ascites
[42,43]. A possible interpretation of these discrepancies
could take into consideration the fact that eﬀective cir-
culating volume does not depend only on vascular
peripheral resistance, but also on a series of other fac-
tors (Table 6) which are prone to be altered in patients
with cirrhosis [44].
A recent study investigated cardiac output in patients
who developed type-1 HRS following spontaneous bac-
terial peritonitis, and observed that the development of
type-1 HRS was associated with a decrease in arterial
pressure, a marked decrease in cardiac output, and a
marked activation of the systemic vasoconstrictor sys-
tems, but was not associated with a further decrease of
peripheral vascular resistance [45]. A further study
investigated the clinical course of cirrhotic patients
before and after the onset of HRS. Patients who devel-
oped HRS had lower baseline values of arterial pressure
and cardiac output and higher baseline values of plasma
renin activity and plasma norepinephrine concentrationTable 6
Determinants of eﬀective circulating volume (Ref. [44])
- Systemic vascular resistance
- Blood volume
- Redistribution of blood volume
- Total vascular compliance
- Cardiac output
- Arterial complianceas compared with those who did not develop this com-
plication. In addition, patients who developed HRS
had a further reduction of arterial pressure and cardiac
output and a further increase of plasma renin activity
and of plasma norepinephrine at the time of the onset
of HRS [46]. Taking together these ﬁndings, it may be
hypothesized that an hyperdynamic circulation is essen-
tial for the maintenance of an eﬀective blood volume in
patients with cirrhosis and that a decrease of cardiac
output, due to a precipitating event such as a bacterial
infection or to other factors, can lead to a severe eﬀec-
tive hypovolemia, a severe arterial vasoconstriction,
thus precipitating HRS.
The reasons why cardiac output decreases in end-
stage liver disease is still poorly elucidated, but in recent
years several speciﬁc cardiac abnormalities have been
recognized, including reduced systolic and diastolic
responses to stress stimuli, electrophysiological repolar-
ization changes, and enlargement of cardiac chambers.
Overall, these abnormalities are commonly termed as
‘‘cirrhotic cardiomiopathy” [47]. In addition, other fac-
tors, such as the release of endotoxins, or a further
release of biologically active substances (inﬂammatory
cytokines, nitric oxide, carbon monoxide and other
vasoactive substances evoked by the reaction to bacte-
rial infection) may further impair cardiac function in
patients with end-stage liver disease. Furthermore, a
severe sepsis or a septic shock is often associated with
adrenal insuﬃciency in patients with cirrhosis and asci-
tes and it correlates with hemodynamic instability and
the development of HRS in these patients [48,49]. How-
ever, several ﬁndings suggest that the decrease in cardiac
output in cirrhotic patients who are going to develop
HRS is mainly related to a reduction of the venous return
of blood to the heart (pre-load). The reasons for this are
that (i) the reduction of cardiac output in these patients
is not associated with an increase in cardiopulmonary
pressure [46,47]; (ii) the hemodynamic scenario which
represents the basis of HRS may be frequently reverted
by the insertion of a transjugular intravenous porto-
systemic shunt (TIPS) which increases pre-load, and
consequently cardiac output [50].
Further, pathophysiological issues are still under
debate, including (i) the pathophysiological diﬀerence
between type-1 and type-2 HRS, and (ii) the role of
intrarenal vasoconstrictors and vasodilators in the path-
ogenesis of HRS. It is generally held that type-1 HRS in
cirrhosis is often precipitated by bacterial infections or
gastrointestinal bleeding, and often develops in a con-
text of multi-organ failure characterized by heart failure,
encephalopathy, and further impairment in liver func-
tion. This complex clinical situation is frequently deﬁned
as ‘‘acute on chronic liver failure”. On the contrary,
type-2 HRS develops spontaneously in many patients
with cirrhosis and ascites representing the real func-
tional renal failure associated with cirrhosis. However,
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put is essential for the occurrence of type-2 HRS, as it
appears to be for the development of type-1 HRS.
The administration of an antagonist of the endothe-
lin’s receptors has been shown to improve renal perfu-
sion in patients with HRS without aﬀecting arterial
pressure systems, demonstrating that endothelin may
mainly act as an intrarenal vasoconstrictor [51]. This
interpretation has been recently challenged by a study
showing that the administration of a non-selective endo-
thelin receptor antagonist cause a deterioration of renal
function in patients with type 2 HRS [52]. Thus, the role
of endothelin in the pathogenesis of HRS needs further
investigation. Other studies in patients with cirrhosis
and ascites have reported an increase in intrarenal
release of other very potent vasoconstrictors, such as
20-HETE and leukotrienes [53–56].
Finally, in cirrhotic animals with ascites a progres-
sive renal failure may be provoked by the administra-
tion of inhibitors of the renal release of local
vasodilators, which include prostaglandins E2 e I2
[57], endogenous natriuretic peptides [58] and nitric
oxide [56]. Conversely, in cirrhotic patients with ascites
the administration of non-steroidal anti-inﬂammatory
drugs may cause an acute form of renal failure which
is quite similar to HRS for clinical and biochemical
aspects [59].5. Therapy of HRS
Orthotopic liver transplantation (OLT) represents the
ideal treatment option in cirrhotic patients with HRS,
because of its ability to remove the main causes of this
complication (portal hypertension and liver failure).
However, the presence of HRS at the time of transplant
has a negative inﬂuence on the transplant outcome as
assessed by survival, costs and quality of life [60]. This
inﬂuence is not very marked, however, since survival
rate averages 60% at three years, compared with an
expected 70–80% in patients without HRS. Patients with
HRS undergoing OLT have an increased risk of compli-
cations after OLT, spend a longer time in the intensive
care unit, and in hospital, and overall have a higher
in-hospital mortality. As far as renal function is con-
cerned, soon after OLT glomerular ﬁltration rate further
decreases in patients with HRS because of surgery stress,
infections, use of immunosuppressants, and other fac-
tors, so that many patients require hemodialysis (35%
as compared with 5% of patients without HRS at the
time of OLT) [60]. Despite the prompt correction of
the hemodynamic and neurohumoral abnormalities
which is clearly apparent within one month after OLT
[61], glomerular ﬁltration rate only partially recovers,
reaching 30–40 ml/min by 1–2 months. This moderate
renal insuﬃciency persists during follow-up, and mayprogress to an end-stage renal failure, if the immunosup-
pressive strategy is not adequate [62].
Up to the end of the 90’s very few patients with cir-
rhosis and HRS underwent OLT, since, due to the rapid
evolution of Type-1 HRS, most patients died before
OLT could be performed. The introduction of MELD
and the strategy of stratifying OLT priority according
to MELD, have partially solved this problem, since
patients with high serum creatinine values have now a
higher priority for OLT. In addition, from the end of
the 90’s new treatment options for HRS have been pro-
posed. Among them, the use of albumin and vasocon-
strictors has proved to be an eﬀective ‘‘treatment
bridge” towards OLT, thus increasing the number of
patients with type-1 HRS who reach OLT [63]. These
new therapeutical options will be discussed separately
for type-1 and type-2 HRS.
5.1. Therapeutic options for type 1 HRS
The eﬃcacy of TIPS in the treatment of type-1 HRS
has been evaluated only in a few pilot studies [50,64]. A
signiﬁcant suppression of the endogenous vasoconstric-
tor systems and a decrease in s-creatinine levels were
observed after TIPS in most patients, but the rate of the
s-creatinine decrease was slower than that generally
reported after albumin infusion and vasoconstrictors.
The reversal of type-1 HRS was observed in 57–71% of
patients. The recurrence of HRS was rare, provided that
no TIPS dysfunction occurred. Survival rates at 1 and 3
months ranged between 71% and 100% and 28.5% and
64%, respectively. Both studies excluded patients with a
history of severe encephalopathy, or serum bilirubin lev-
els over 85 lmol/l (5 mg/dl) or Child–Turcotte–Pugh
score >12 (all conditions frequently observed in unse-
lected patientswith type-1HRS); therefore the applicabil-
ity of TIPS in this clinical setting is rather limited.
The most promising new therapeutical option for
Type-1 HRS is based on the recent pathophysiological
acquisitions about the relationships between splanchnic
vasodilation and renal vasoconstriction that were
reported above. Indeed, a series of recent studies have
suggested that the prolonged use of vasopressin deriva-
tives, such as ornipressin [65,66] or terlipressin [67–75],
or of a-adrenergic agonists (noradrenaline, midodrine)
[76–79] in association with the prolonged infusion of
human albumin are useful in the treatment of patients
with type-1 HRS. Overall, although most of the infor-
mation comes from non-randomised studies, the eﬀect
of this treatment can be summarized as follows: (1)
recovery of renal function is obtained in 40–60% [66–
78], (2) the recovery of renal function is maintained in
over 70–80% of patients after the treatment is with-
drawn [67–79], (3) if recurrent HRS occurs after treat-
ment withdrawal, re-treatment is often eﬀective, (4)
40–50% one-month transplant-free survival can be
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untreated patients [80,81], (5) in most cases dilutional
hyponatremia associated with HRS improves.
The choice of drug and the schedule of treatment var-
ied across these studies. To date, terlipressin is the most
widely used vasoconstrictor in the treatment of type-1
HRS [67–79]. In several pilot studies, terlipressin has
been used in more than 200 patients either as i.v. bolus
injections starting from an initial dose of 0.5 mg every 4–
6 h or as a continuous intravenous infusion starting
from an initial dose of 2 mg/day. In patients without a
response (reduction of serum creatinine less than 30%
in 3 days), the initial dose of terlipressin was generally
doubled. The maximum doses of terlipressin used in
the treatment of type 1 HRS were 2 mg as i.v. bolus
injections every 4–6 h or 12 mg/day in continuous infu-
sion. Partial or complete reversal of type-1 HRS was
observed in almost 59% of patients. In two studies in
which terlipressin was given alone, recovery of renal fail-
ure was less frequent that in the studies in which terli-
pressin was associated with albumin [73,77]. Up to
now, a shorter experience is available on midodrine or
octreotide. These drugs were used in three pilot studies
in a total of 79 patients [76,79,80]. A complete recovery
of renal failure was observed in 49% of patients. In most
patients midodrine administration started at 5-10 mg
t.i.d. orally, with the goal of increasing the dose to
12.5 or 15 mg t.i.d. if a reduction of serum creatinine
was not observed. Octreotide administration started at
100 lg subcutaneously t.i.d. with the goal of increasing
the dose to 200 lg subcutaneously t.i.d. if a reduction
of serum creatinine was not observed. Experience of
the use of i.v. norepinephrine in the treatment of
patients with type-1 HRS is much more limited [78].
Nevertheless, the preliminary results of the two ﬁrst
controlled clinical trials comparing terlipressin and albu-
min with albumin alone did not conﬁrm a beneﬁcial
eﬀect of terlipressin and albumin on 2 or 3 month sur-
vival in patients with type-1 HRS (Table 7) [82,83].
Unfortunately, detailed information on these trials is
still unavailable, and it is diﬃcult to draw ﬁrm conclu-
sions from these preliminary data. In particular, it is
unclear if the diﬀerences between the two outcome mea-
surements, i.e. recovery of renal function and survival,
are related to a transient beneﬁt in renal function, orTable 7
Terlipressin and albumin vs. albumin alone in cirrhotic patients with type-1 he
[83]
Terlipressin + Albumin Album
Response rate (%) 39* 9
Survival rate (%) At 3 months At 3 m
26 18
Preliminary results of two randomised controlled studies (Ref. [82,83]).
* p < 0.05.
** p < 0.01.to the occurrence of diﬀerent complications eventually
leading to death. Nevertheless, the overall survival,
which was much higher than usually expected, is surpris-
ing, particularly in the American study; this was partic-
ularly evident for patients who received the conventional
treatment, which suggests the possible use of diﬀerent
inclusion criteria or a possible beneﬁt from the use of
albumin by itself.
The recent introduction of innovative techniques for
extracorporeal liver function support like the molecular
adsorbent recirculating system (MARS) has made it
possible to recover hepatic function to some extent, even
transiently. When MARS was applied to the treatment
of type-1 HRS, a possible beneﬁt from this treatment
was suggested as a consequence of removal of albu-
min-driven vasoactive substances such as nitric oxide,
tumor necrosis factor, and other proinﬂammatory cyto-
kines. Such eﬀects resulted in clinical improvement in
renal function, and this also produced a positive eﬀect
on 30 day survival in these patients (37.5% versus 0%)
[84]. So, it is easy to hypothesize that in the near future
MARS should be tested as an additional treatment
together with vasoconstrictor and albumin in the treat-
ment of type-1 HRS in patients with marked impair-
ment of liver function.
Although the most important aim of treating patients
with type-1 HRS with vasoconstrictors and albumin is
that of bridging these patients towards OLT, it is evident
that such treatment should also be tested in non-trans-
plant candidates, with the aim of prolonging survival,
since in some patients possible survival beneﬁts are far
from trivial [85].
5.2. Therapeutic options for type-2 HRS
The main clinical problem in patients with type-2
HRS is not acute renal failure, but refractory ascites.
TIPS is frequently used as an alternative to therapeutic
paracentesis in the treatment of refractory ascites associ-
ated or not with type-2 HRS. Up to now, ﬁve controlled
studies comparing therapeutic paracentesis to TIPS in
refractory or tense ascites have been published [86–90].
Although no separate analysis for patients with type-2
HRS were performed in these trials, it is reasonable to
conclude that (1) TIPS is more eﬀective than paracente-patorenal syndrome
[82]
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thy is greater in patients who are treated with TIPS, and
(3) survival is similar. Nevertheless, recent meta-analy-
ses show that TIPS signiﬁcantly improve transplant-free
survival in cirrhotic patients with refractory ascites [91–
93]. There are only two pilot studies speciﬁcally address-
ing the eﬀect of TIPS in patients with type-2 HRS
[50,94], but there are reports of series of consecutive
patients treated with TIPS, and no comparison with dif-
ferent treatments is possible. In both reports s-creatinine
decreased, and ascites was more easily controlled. The 1-
year survival was encouraging (70%) [50].
The eﬀects of vasoconstrictors and albumin in type-2
HRS treatment have been the subject of few studies,
none of which is an RCT. The percentage of response
to the treatment in terms of recovery of renal function
was similar to that reported in patients with type-1
HRS [72,73,94], while survival was clearly longer
(100% at 3 months), as expected from the data on the
natural history of this condition.
5.3. Prevention of HRS
Being the consequence of many complex alterations
in systemic and local hemodynamics, HRS could be
unspeciﬁcally prevented by all treatments contrasting
these alterations. In this context, prevention of bacterial
infections, and in particular of SBP, also plays a role in
the prevention of HRS following infections. This has
been demonstrated in a clinical trial of long-term nor-
ﬂoxacin prophylaxis of SBP, in which a decrease in the
risk of developing type-1 HRS was also shown [95]. A
more speciﬁc approach to the prevention of SBP-
induced HRS has been suggested by Sort et al. in a
RCT of intensive albumin treatment of SBP (1.5 g/kg
b.w. the ﬁrst day, plus 1 g/Kg b.w. the third day) [96].
In this trial, patients receiving this intense albumin treat-
ment showed a marked decrease in risk of developing
HRS, and in hospital and 3-month mortality (relative
risk decrease ranging from half to two thirds). The
mechanisms underlying this important preventive eﬀect
of albumin on the occurrence of HRS after SBP are
not fully elucidated, but these may include the preven-
tion of further reduction of the eﬀective circulating vol-
ume mediated by an increase in cardiac preload and/or
an improvement of cardiac contractility [97]. This latter
eﬀect of albumin is probably related to its ability to bind
NO and proinﬂammatory cytokines, which may cause a
negative inotropic eﬀect on the heart [98].6. Conclusions
The most recent advancements in our understanding
of the pathophysiology of HRS are the basis of the new
therapeutic interventions. Besides OLT, which is thebest treatment but is seldom applicable, the combined
use of vasoconstrictors and albumin is the most promis-
ing option. However, further studies are needed to prove
its clinical usefulness.References
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